{
    "summary": "The 'Stop STALLING Act' aims to empower the Federal Trade Commission (FTC) to combat the filing of 'sham' citizen petitions designed to delay the approval of generic drugs and biosimilars. The bill defines 'sham petitions' and allows the FTC to take action, including levying civil penalties, against those who submit them. It clarifies that this action is in addition to existing antitrust laws and remedies and specifies that the law applies to covered petitions filed after the enactment date.",
    "tags": [
        "Healthcare",
        "Consumer protection",
        "Technology regulation",
        "Healthcare access",
        "Opioid crisis",
        "Bipartisanship"
    ],
    "category": "Healthcare & Public Health"
}